Valuation: Gilead Sciences, Inc.

Market Cap 161B 141B 131B 120B 228B 15,428B 232B 1,561B 612B 7,576B 605B 592B 26,165B P/E 2026 *
-46.8x
P/E 2027 * 16.7x
Enterprise Value 171B 150B 139B 128B 241B 16,334B 246B 1,652B 648B 8,021B 641B 627B 27,701B EV / Sales 2026 *
5.6x
EV / Sales 2027 * 4.98x
Free-Float
99.88%
Yield 2026 *
2.5%
Yield 2027 * 2.59%
1 day+0.93%
1 week+1.23%
Current month+3.85%
1 month+5.56%
3 months-5.62%
6 months+7.76%
Current year+6.90%
1 week 127.94
Extreme 127.935
137.7
1 month 122.43
Extreme 122.43
137.7
Current year 116.88
Extreme 116.88
157.29
1 year 107.75
Extreme 107.75
157.29
3 years 62.07
Extreme 62.07
157.29
5 years 57.16
Extreme 57.165
157.29
10 years 56.56
Extreme 56.56
157.29
Manager TitleAgeSince
Chief Executive Officer 61 2019-02-28
Director of Finance/CFO 56 2019-10-31
Compliance Officer - 2025-12-17
Director TitleAgeSince
Director/Board Member 58 2016-08-18
Director/Board Member 73 2017-12-31
Director/Board Member 72 2018-05-08
Date Insider Type Main position Quantity % Market Cap.
Jun. 30Sell

Chief Executive Officer

-15,000 0.0012%
Jun. 14Sell

Chief Financial Officer

-3,000 0.0002%
Jun. 14Sell

Executive/Senior Manager

-3,000 0.0002%
Change 5-day change 1-year change 3-year change Capi.($)
+0.97%+1.23%+17.06%+71.05% 161B
-0.14%-0.90%+48.78%+173.57% 1,060B
+0.25%-0.67%+64.26%+62.21% 619B
-0.54%-3.10%+28.89%+84.79% 438B
-1.75%-0.33%+28.33%+23.58% 333B
+0.24%-0.42%+29.19%+47.26% 282B
-1.75%-10.57%+18.27%+22.07% 267B
+0.67%+1.03%-26.81%-37.96% 218B
-1.25%-2.08%+20.80%+57.60% 196B
+1.26%+3.10%-3.53%-32.18% 138B
Average -0.15%-3.06%+22.52%+47.20% 371.17B
Weighted average by Cap. -0.18%-3.00%+34.25%+79.94%

Financials

2026 *2027 *
Net sales 30.47B 26.72B 24.75B 22.77B 43.07B 2,916B 43.91B 295B 116B 1,432B 114B 112B 4,945B 32.37B 28.39B 26.29B 24.19B 45.76B 3,098B 46.65B 313B 123B 1,521B 122B 119B 5,254B
Net income -3.37B -2.96B -2.74B -2.52B -4.77B -323B -4.86B -32.66B -12.81B -159B -12.67B -12.39B -547B 9.55B 8.37B 7.76B 7.14B 13.5B 914B 13.76B 92.45B 36.26B 449B 35.85B 35.07B 1,550B
Net Debt 9.46B 8.3B 7.69B 7.07B 13.37B 905B 13.63B 91.6B 35.92B 445B 35.52B 34.75B 1,536B -96.43M -84.58M -78.34M -72.08M -136M -9.23B -139M -934M -366M -4.53B -362M -354M -15.65B
Logo Gilead Sciences, Inc.
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.2%): for the treatment of HIV (71.8% of net sales), oncology diseases (11.2%), hepatitis B virus (11.1%), Ebola virus (3.2%) and other (2.7%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.8%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (70.9%), Europe (17.2%) and other (11.9%).
Employees
17,000
Date Price Change Volume
26-07-13 $131.14 +1.01% 2,213,514
26-07-10 $129.83 -3.72% 5,935,997
26-07-09 $134.84 -0.72% 5,839,339
26-07-08 $135.82 -0.40% 8,454,142
26-07-07 $136.36 +5.21% 9,177,296
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
129.83USD
Average target price
158.30USD
Spread / Average Target
+21.93%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GILD Stock